Giving infliximab the best chance of working for Hidradenitis Suppurativa (HS) from the start means getting the dose right. In a retrospective study led by Dr. Christopher Sayed of University of North Carolina and published September 2019 in the Journal of the Academy of Dermatology, the authors investigated the variety of ways infliximab was used to treat people with HS.
An early study for a new injectable treatment shows improvement in Hidradenitis Suppurativa (HS) activity and pain scores while demonstrating safety. Dr. Alice Gottlieb of Icahn School of Medicine at Mount Sinai, New York led the research investigating the results of bermekimab use in 42 patients with Hidradenitis Suppurativa. The results were recently published in the Journal of Investigative Dermatology.